We have previously reported that an osteosarcoma vaccine generated by ex vivo transfection of B7 -1 cDNA induces protective as well as curative immunity against B7 -1 -negative parental osteosarcoma. Because establishment of human osteosarcoma cell lines, which is a prerequisite for ex vivo gene transfer, is rarely successful, we, in the present study, investigated the therapeutic efficacy of adenovirus -mediated in vivo B7 -1 gene transfer to pre -established primary tumor as well as pulmonary metastasis of osteosarcoma. Adenovirus -mediated rat B7 -1 gene transfer induced ( a ) expression of B7 -1 molecules in osteosarcoma cells by both in vitro and in vivo infection procedures, ( b ) curative immunity against pre -established primary osteosarcoma and, subsequently, hosts gained protection against additional challenge of parental B7 -1 -negative osteosarcoma cells, ( c ) systemic immunity against preestablished pulmonary metastasis, and ( d ) activation of regional lymph node CD4 + T cells, expansion of dendritic cells and natural killer cells and the secretion of interferon -. These findings collectively support the therapeutic value of adenovirus -mediated in vivo gene transfer on osteosarcoma, which is of greater simplicity than cell -based B7 -1 vaccine, and represent an attractive strategy for therapy of patients with metastatic osteosarcama who acquired resistance to current therapeutic protocols.
A lthough many tumors display a variety of tumorassociated antigens that can be recognized by T cells, 1, 2 most of them eventually escape from host cellular immune surveillance. Activation of naive T cells and development of adaptive immunity require two signals. 3, 4 The first signal is initiated by the binding of a major histocompatibility complex ( MHC )/ antigen complex to the T-cell receptor and the second signal by the binding of costimulatory ligands to their receptors. Tumor cells commonly express MHC molecules, but do not usually express costimulatory molecules, leading presumably to the failure of T-cell activation. 5 A variety of transmembrane molecules have been defined, which provide costimulatory second signals through their receptors on T cells, including members of the immunoglobulin ( Ig) family [intercellular adhesion molecule ( ICAM )-1, ICAM -2, vascular cell adhesion molecule ( VCAM )-1, and the B7 subfamily ], 6, 7 the integrin family [leukocyte function associated antigen (LFA -3 )], 7 and the tumor necrosis factor ( TNF ) family [CD40 ligand ( L), OX40L, 4 -1BBL, and LIGHT]. 3 The first identified member of the B7 costimulatory family of molecules is B7 -1 (CD80 ). The successful induction of an anti -tumor immune response has been reported in a number of tumor models by using B7 -1-transfected tumor cells as a vaccine. 8 -10 Osteosarcoma is a highly malignant bone tumor that most commonly affects adolescents and young adults. Advances in multimodality treatments consisting of aggressive adjuvant chemotherapy and wide tumor resection have markedly improved the prognosis of patients with osteosarcoma. However, 30 -40% of the patients still encounters therapeutic failures. 11, 12 Treatment of patients with osteosarcoma, especially those who have acquired resistance to current chemotherapy protocols, remains a major challenge. Active immunotherapy is a potential clue to overcome such therapeutic difficulties. Using a syngeneic rat model system, we previously demonstrated that exogenous expression of B7 -1 in osteosarcoma cells induced curative, as well as protective, immunity against B7 -1 -negative parental osteosarcoma. 13 In that model, an osteosarcoma cell vaccine was generated by ex vivo transfection of B7 -1 cDNA into osteosarcoma cells. However, this strategy is not readily applicable to the clinical situations because human osteosarcoma cell lines is not easily established. One approach will be the direct in vivo transfection of B7 -1 gene. The recombinant adenovirus is one of the attractive in vivo gene deliverers because of its ability to efficiently transduce genes into a wide variety of proliferating and nonproliferating cells 14 and to produce large quantities of the virus in purified form. 15 In fact, adenovirus -mediated gene delivery of B7 -1 and /or cytokines has been shown to induce systemic immunity in several tumor models. 16 -21 However, no such attempts have been employed for osteosarcoma, in which pre -established micropulmonary metastasis is the principal therapeutic target.
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In the current study, we investigated the efficacy of adenovirus -mediated in situ B7 -1 gene transfer in expression of B7 -1 molecules and induction of anti -tumor immunity against pre -established primary as well as metastatic osteosarcoma using rat syngeneic experimental and spontaneous pulmonary metastasis models. In addition, we determined the immune constitutes critically involved in eradication of these osteosarcoma tumors.
Materials and methods

Rats, cell lines, and reagents
Male Fischer 344 ( F344 ) rats and male Lewis ( LEW ) rats, 6 weeks old, were purchased from Japan SLC (Hamamatsu, Japan ), and housed in a specific pathogen -free animal facility in our institute.
Osteosarcoma cell lines, MSK -8G and MSK -4E, derived from a F344 rat were kindly provided by the Department of Oral Surgery, Chiba University, Japan. 22 A gliosarcoma cell line, T9, was developed from a F344 rat as described elsewhere. 23 These cell lines were maintained in DMEM ( Gibco, Grand Island, NY ) containing 10% fetal calf serum ( Gibco ), vitamin solution, sodium pyruvate, nonessential amino acids, and L -glutamate, and were cultured at 378C in 5% CO 2 .
Monoclonal antibodies (mAbs) used were mouse anti -rat B7 -1 ( 3H5 ), 24 mouse anti -rat MHC class I ( OX -18; PharMingen, San Diego, CA ), mouse anti -rat CD32 ( D34 -485; PharMingen ), PE -conjugated mouse anti -rat CD3 (G4.18; PharMingen ), PE -conjugated mouse anti -rat CD4 ( W3/ 25; Serotec, Oxford, UK ), FITC -conjugated mouse anti -rat CD44H (OX -49; PharMingen), FITCconjugated mouse anti -rat CD4 (OX -35; PharMingen ), PE -conjugated mouse anti -rat CD8 ( OX -8; PharMingen ), PE -conjugated mouse anti -rat CD45RA (OX -33; PharMingen ), FITC -conjugated mouse anti -rat RT1B ( OX -6; PharMingen ), PE -conjugated mouse anti -rat macrophage ( HIS36; PharMingen ), and FITC -conjugated mouse antirat NKR -PIA ( 10/ 78; PharMingen) mAb. A fusion protein, CTLA -4Ig, which consists of an extracellular portion of mouse cytolytic T lymphocyte-associated antigen -4 ( CTLA -4 ) and Fc portion of human immunoglobulin G1, was prepared as described previously. 25 
Preparation of recombinant adenoviral vectors
Total RNA was isolated from LEW splenocytes using the reagent TRISOL ( Life Technologies, Grand Island, NY ) and a cDNA fragment encoding the rat B7 -1 ( À 15 to +991 ) was generated by reverse transcription polymerase chain reaction ( RT-PCR ) amplification. Briefly, cDNA was synthesized using oligo ( dT ) as a random primer. PCR was performed using LA TaqTM polymerase (Takara, Otsu, Japan ) under the condition of denaturation at 948C for 1 minute, annealing at 508C for 1 minute, and extension at 728C for 1 minute. This was performed using the sense (5 0 -AGAGCATCTGAAGCCATGGCTTAC -3 0 ) and antisense (5 0 -GCTAAAGGAAGGCAAATGGCTACC -3 0 ) primers designed to anneal to the 5 0 -and 3 0 -ends of the rat B7 -1 cDNA sequence as deposited in GenBank. The amplified fragment of 1006 bp was ligated into the PCR II plasmid using TA cloning kit (Invitrogen, Carlsbad, CA ). The resultant PCR II plasmid was amplified and purified by alkaline lysis. Following sequencing, a recombinant adenovirus vector encoding the rat B7 -1 cDNA was generated by COS -TPC method 26 in 293 cells using Adenovirus Expression Vector Kit ( Takara ). Briefly, the rat B7 -1 cDNA fragment was excised from the PCR II plasmid and inserted into a cassette cosmid vector that contained an entire adenovirus type 5 genome except the E1 and E3 regions ( pAxCA -rB7-1). A recombinant adenovirus was constructed by in vitro homologous recombination in 293 cells by using pAxCA -rB7-1 and the adenovirus DNA terminal protein complex. The desired recombinant adenovirus, designated Adex -rB7-1, was propagated in 293 cells and purified by two rounds of cesium chloride density centrifugation as described previously. 15 The concentrated virus was dialyzed in phosphate -buffered saline ( PBS )-10% glycerol. The titer of the virus stock was calculated by a plaque formation assay using 293 cells. The adenovirus vector expressing the -galactosidase ( -gal ) protein was generated by the same method and designated Adex -LacZ.
Adenoviral gene transfer and flow cytometry
For in vitro adenoviral infection, 1Â10 5 cells were incubated with Adex -rB7-1 at the indicated multiplicity of infection ( MOI ) for 1 hour and incubated at 378C in DMEM containing 10% fetal calf serum. Cell surface expression of the transfected gene products was confirmed by flow cytometry using 3H5 mAb or CTLA -4Ig 48 hours after infection. Expression of rat MHC class I molecules on MSK -8G cells was determined before and after adenoviral infection by flow cytometry using OX -18 mAb.
In in vivo gene transfer experiments, MSK -8G cells (1Â10 6 ) were inoculated into the right flank of syngeneic F344 rats. Three weeks after tumor cell inoculation, 5Â10 8 plaque -forming units (pfu ) of Adex -rB7-1 or Adex -LacZ were injected intratumorally into one injection site. On 3, 7, and 14 days after viral injection, subcutaneous tumors were resected, minced, and incubated with collagenase ( Wako, Osaka, Japan ) to be dispersed. B7 -1 expression on the dispersed cells was determined by flow cytometry using 3H5 mAb.
Flowcytometric analysis was performed by indirect immunofluorescence staining as follows. Cells were first incubated with 3H5 mAb or CTLA -4Ig for 1 hour at 48C. After washing, cells were incubated with FITC -conjugated gout anti -mouse IgG (Jackson, West Grove, PA ) for 3H5 mAb, or FITC -conjugated goat anti -human IgG (Fc ) ( Jackson) for CTLA -4Ig. To detect the expression of the rat MHC class I molecules, cells were incubated with D34 -485 mAb for preclear, followed by incubation with PEconjugated OX -18 mAb. Stained cells (2Â10 4 cells ) were analyzed in a FACScan flow cytometer ( Becton Dickinson, Mountain View, CA ).
Tumor models and treatment protocols
Efficacy of adenovirus -mediated in situ B7 -1 gene transfer in induction of anti -tumor immunity was evaluated in the primary tumor and pre -established pulmonary metastasis models. Treatment protocols were designed on the basis of a single intratumoral injection of Adex -rB7-1 or Adex -LacZ.
In the primary tumor model, MSK -8G cells ( 1Â10 6 ) were inoculated subcutaneously into F344 rats and 5Â10 8 pfu of Adex -rB7 -1 or Adex -LacZ were injected into the subcutaneous tumor 3 weeks after cell inoculation. At that time, the diameter of the tumor reached approximately 8 mm. The tumor volume was calculated weekly for 12 weeks as lengthÂwidth 2 /2. Protective immunity was evaluated by the additional challenge of MSK -8G or T9 cells (1Â10 6 ) at 7 weeks in rats that had been inoculated with MSK -8G cells and received an intratumoral viral injection. The volume of challenged MSK -8G tumors was also scored weekly.
The therapeutic efficacy of intratumoral injection of Adex -rB7 -1 on pre -established pulmonary metastasis was assessed by experimental and spontaneous metastasis models. In the experimental metastasis model, MSK -8G cells (1Â10 6 ) were injected simultaneously into the subcutis and the tail vein of rats, which allowed to establish a subcutaneous tumor and pulmonary metastasis, respectively. Adex -rB7 -1 ( 5Â10 8 pfu ) or Adex -LacZ was injected into the subcutaneous MSK -8G tumor at 3 weeks and the number of metastatic nodules in the lung was counted at 6 weeks. In the spontaneous metastasis model, highly metastatic MSK -4E cells ( 1Â10 7 ) were injected subcutaneously into rats and Adex -rB7 -1 ( 5Â10 8 pfu ) or AdexLacZ was injected into the subcutaneous tumor at 5 weeks. The number of metastatic nodules in the lung was counted at 10 weeks. Five rats were used in each experiment. The statistical significance was determined by Student's t test using the statistical analysis software, Statcel ( OMS, Tokorozawa, Japan ). A probability of < .05 was accepted as significant difference.
CTL assay
Cytotoxic T lymphocyte (CTL ) activity was evaluated by the JAM test, a simple assay detecting DNA fragmentation and cell death using [ 3 H ]thymidine. 27 Briefly, splenocytes or regional lymph node cells were obtained at 12 weeks from rats receiving Adex -rB7-1 or Adex -LacZ treatment and used as effector cells. The effector cells ( 2Â10 7 ) were first stimulated by coculturing with MSK -8G (1.6Â10 5 ) for 3 days in RPMI (GIBCO ) medium without FCS. Serial dilutions of the effector cells were incubated in a roundbottom 96 -well plate with 1Â10 4 of MSK -8G or T9 target cells, which had been labeled with [ 3 H ]thymidine for 6 hours. After 4 hours of incubation, the cell aliquots were aspirated onto fiber glass filters using a cell harvester. The filters were washed, dried, and soaked into liquid scintillation fluid and the radio activity was counted in a liquid scintillation counter. The percent -specific lysis was calculated as follows: [( spontaneous cpm À experimental cpm )/ spontaneous cpm ]Â100.
Histological analysis
The subcutaneous tumors and the lungs were obtained from rats in the experimental metastasis model at 4 and 6 weeks. Tissues were fixed in 10% formalin, sectioned at 4-6 m thickness, and stained with hematoxylin and eosin.
Flowcytometric analysis of regional lymph node cells
Regional lymph node cells were obtained from rats 7 days after adenoviral treatment ( n =2 ). The cells were washed in PBS supplemented with 0.2% bovine serum albumin and 0.1% NaN 3 and incubated with one of the following mAbs: G4.18, W3 /25, OX -49, OX -35, OX -8, OX -33, OX -6, HIS36, and 10 /78. Cells were incubated with D34 -485 mAb to avoid nonspecific binding, then followed by incubation with FITC -or PE -conjugated mAb. Cells were also incubated with mouse anti -rat dendritic cells (DCs ) ( OX -62; PharMingen ) mAb, washed, and incubated with PEconjugated anti -mouse Ig kappa light chain ( 187.1; PharMingen ).
Real time PCR analysis
Regional lymph node cells were obtained from rats 7 days after adenoviral treatment. Total RNA was isolated from these 
Results
Efficacy of in vitro and in vivo B7 -1 gene transfer into MSK -8G osteosarcoma cells
To investigate the therapeutic value of adenovirus -mediated B7 -1 gene transfer in pre -established osteosarcoma, we constructed a recombinant adenovirus vector that carries the rat B7 -1 cDNA ( Adex -rB7 -1). Using a rat osteosarcoma cell line, MSK -8G, we first evaluated the ability of AdexrB7-1 to induce B7 -1 expression by an in vitro infection procedure. Flowcytometric analysis using anti -rat B7 -1 mAb showed undetectable levels of endogeneous B7 -1 molecules in MSK -8G cells (data not shown ). In vitro infection of MSK -8G cells with Adex -rB7 -1 clearly induced B7 -1 expression on the cell surface in a dose ( MOI )-dependent manner. Notably, larger than 99% of cells expressed B7 -1 molecules when Adex -rB7-1 with MOI of 50 or more was applied. Consistent with the reactivity of anti-B7 -1 mAb, CTLA -4Ig, the soluble form of the B7 -1 ligand also reacted with MSK -8G cells depending on the MOI of Adex -rB7-1 applied. MHC class I molecules were expressed constitutively on MSK -8G cells and remained unchanged after infection with Adex -rB7 -1.
Subsequently, we evaluated the efficacy of in vivo B7 -1 gene transfer. In this analysis, MSK -8G cells were injected subcutaneously into syngeneic F344 rats to develop a tumor, and Adex -rB7 -1 or Adex -LacZ was intratumorally injected at 3 weeks. Three, 7, and 14 days after the viral injection, cells were dispersed from the tumor and B7 -1 expression was determined by flow cytometry using anti -B7 -1 mAb. As shown in Figure 1 
Effect of intratumoral injection of Adex -rB7 -1 in pre -established primary tumor
We then evaluated the effects of intratumoral injection of Adex -rB7 -1 in pre -established primary tumors. As shown in Figure 2a , an intratumoral injection of Adex -LacZ into subcutaneous MSK -8G tumors did not modify the subsequent tumor growth compared to MSK -8G tumors without viral injection. In marked contrast, a single intratumoral injection of Adex -rB7-1 completely eradicated the MSK -8G tumor in three of five rats and significantly reduced the tumor growth in the remaining two rats. The tumor volume of Adex -rB7 -1 -injected tumors was 257.0 ± 101.7 mm 3 at 3 weeks, 334.5 ± 138.2 mm 3 at 4 weeks, 95.7 ± 82.1 mm 3 at 5 weeks, and 62.1± 72.9 mm 3 at 6 weeks. In a 12 -week observation period, none of the three eradicated MSK -8G tumors showed recurrent tumor growth.
To determine whether an intratumoral injection of AdexrB7-1 induced protective immunity, parental MSK -8G cells were reinoculated subcutaneously 4 weeks after the viral injection ( Fig 2b ) . Notably, rats that had received an intratumoral injection of Adex -rB7-1 completely protected against challenge with MSK -8G cells, whereas those treated with Adex -LacZ allowed development of MSK -8G tumors. The number of pulmonary metastatic nodules after an adenoviral treatment in the spontaneous pulmonary metastasis models. MSK -4E cells ( 1Â10 7 ) were injected subcutaneously into rats and Adex -rB7 -1 ( 5Â10 8 pfu ) or Adex -LacZ was injected into the subcutaneous tumor at 5 weeks. The number of metastatic nodules in the lung was counted at 10 weeks. Four rats were used for each group. The average numbers of pulmonary metastatic nodules are shown with standard deviation.
Cancer Gene Therapy
Adenoviral B7-1 gene transduction into osteosarcoma H Tsuji et al Rats treated with Adex -rB7 -1 or Adex -LacZ allowed development of T9 tumors, which suggests that Adex -rB7-1 treatment induced the specific anti -tumor immunity against MSK -8G cells.
Cytotoxicity and immunological phenotype of Adex -rB7 -1 -induced anti -tumor immunity
We next determined the specificity of Adex -rB7-1-induced anti -tumor immunity using the JAM test. As shown in Figure 3 , splenocytes or regional lymph node cells prepared from rats that had received an intratumoral Adex -rB7-1 injection showed apparent cytotoxic activity against MSK -8G cells with the maximal lysis of 65% at the E:T ratio of 30:1. In contrast, these cells showed marginal cytotoxicity ( approximately 10% lysis ) against a syngeneic gliosarcoma line, T9, up to the E /T ratio of 30:1. No significant cytotoxic activity was observed in the effector cells obtained from rats treated with Adex -LacZ.
We also examined the number and immunological phenotype of the regional lymph node cells in rats receiving viral treatment. As shown in Figure 4a , Adex -rB7 -1-treated rats yielded a larger number of regional lymph node cells than did Adex -LacZ -treated rats or control rats without viral treatment. The T/ B cell ratio in the lymph node cells did not differ among the rat groups receiving an injection of Adex -rB7-1, Adex -LacZ, or no viral treatment ( Fig 4b) . However, in the T-cell population, CD4 + T cells, especially those in the activated form (CD44H + ), were significantly increased in Adex -rB7 -1 -treated rats (Fig 4c) . Also, an increased number of natural killer ( NK ) cells as well as DCs were detected in the regional lymph nodes in Adex -rB7 -1 -treated rats ( Fig 4d ) . Similar phenotypic changes were observed in splenocytes prepared from Adex -rB7 -1 -treated rats (data not shown).
To examine which cytokines were produced by the regional lymph node cells in Adex -rB7 -1 -treated rats, we conducted real time PCR analysis ( Fig 5 ) . As shown, an intratumoral injection of Adex -rB7-1 significantly increased the mRNA expression of IFN -in regional lymph node cells compared to Adex -LacZ -treated rats or control rats, whereas no apparent difference was observed in the expression levels of IL -4 among these groups.
Therapeutic efficacy of Adex -rB7 -1 on pre -established pulmonary metastasis Finally, we examined the therapeutic efficacy of adenovirusmediated B7 -1 gene transfer on pre -established pulmonary metastasis using experimental and spontaneous metastasis models. In the experimental pulmonary metastasis model, MSK -8G cells were injected simultaneously into the tail Figure 7 Pathohistological analysis of the primary tumors and the pulmonary metastatic foci. Subcutaneous primary tumors were obtained from the rats 7 days after Adex -rB7 -1 ( A ) and Adex -LacZ ( B ) treatment. Lungs were obtained 3 weeks after Adex -rB7 -1( C ) and Adex -LacZ ( D ) treatment of primary tumors. These sections were stained with hematoxylin and eosin ( Â400 ). In ( C ) and ( D ), left columns represent lower magnification ( Â100 ) of lung tissues. ( ! ) Indicates the border between tumor and normal lung. Representative results were shown.
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vein and the subcutis of rats and Adex -rB7 -1 or Adex -LacZ was injected into the subcutaneous MSK -8G tumor at 3 weeks. A single injection of Adex -rB7-1 into the subcutaneous tumor diminished the number of pulmonary metastatic nodules compared to that in untreated rats (20.0 ± 12.2 vs 60.5 ± 10.9 ). On the contrary, an injection of Adex -LacZ failed to yield a significant reduction of pulmonary metastasis (48.8 ± 20.1 ). MSK -4E is another clone of the MSK osteosarcoma line characterized by its potential for spontaneous metastasis ( Hayakawa et al, unpublished data ) . As shown in Figure 6 , subcutaneously inoculated MSK -4E cells developed an average of 13.3 metastatic nodules in the lung at 10 weeks. In this spontaneous metastasis model, Adex -rB7-1 was injected into the subcutaneous MSK -4E tumor 5 weeks after inoculation, leading also to the significant reduction of development of pulmonary metastasis (3.0 ± 1.8). Such reduction was not obtained by Adex -LacZ injection ( 12.3± 5.9 ) .
Histological analysis revealed remarkable infiltration of mononuclear cells into the primary MSK -8G tumors ( Fig 7A ) and pulmonary metastatic nodules (Fig 7C ) in Adex -rB7 -1 -treated rats, whereas no such cell infiltration was observed in the primary (Fig 7B ) or metastatic (Fig 7D ) tumors in Adex -LacZ -treated rats.
Discussion
We have reported previously that an osteosarcoma vaccine, which had been generated by ex vivo transfection of B7 -1 cDNA, induced protective as well as curative immunity by inducing the generation of CTL against B7 -1 -negative parental osteosarcoma in a rat orthotopic transplantation model. 13 However, this strategy is not readily applicable to the clinical situations because development of osteosarcoma cell lines is rarely successful. In the present study, therefore, we tried in vivo transfection using an adenoviral vector that was close to the clinical situations and showed that this strategy was effective in the pre -established primary tumor model as well as pulmonary metastatic model. Experimental therapies by means of intratumoral injection of Adex -B7 -1 and /or cytokines have been reported in several tumor models. 16 -21 In transplanted primary polyoma middle T antigen-induced tumor models, one study showed that intratumoral administration of Adex -B7 -1 resulted in 37.5% complete regression, with the other 62.5% showing partial regression 17 and the other study reported 93% growth delay, without complete regression. 16 However, the combination of Adex -B7 -1 and IL -2 or IL -12 that favors the generation of Th1 type immune responses resulted in 100% 17 and 90% 16 complete regression, respectively. In a melanoma model, tumor cells infected with Adex -B7 -1 in vitro decreased their tumorigenicity, but the growth of established subcutaneous tumors was not affected by intratumoral injection of Adex -B7 -1 18 and they reasoned that the failure is due to the existence of tumor-derived factors that limited the effectiveness of the immune response. Thus, the therapeutic outcome using B7 -1 gene varied significantly. Therefore, cellular and molecular mechanisms involved in anti -tumor immune responses induced by B7 -1 gene therapy should be clarified before further carrying out this therapeutic strategy in clinical settings. The mechanistic information obtained can be used to improve the outcome of future gene therapy.
Immune responses against adenoviral vector -mediated exogenous gene transduction are well described, and it is known that adenoviral gene transduction in several tissues is rapidly terminated mainly due to immunological responses. 28, 29 CTL specifically recognizing adenoviral antigen is generated. 30 Willimsky et al 19 suggested that CTLs recognizing transduced gene product were also induced. In our present data, administration of Adex -LacZ did not significantly modify the MSK -8G tumor growth, which suggests that immune responses against adenoviral antigen and -gal did not significantly play a role in antitumor immune responses in our model. We have not tested whether CTL recognizing adenoviral antigen and -gal were generated in our model. However, we have shown that the expression of MHC was not down -regulated after AdexrB7-1 treatment and CTL recognizing MSK -8G was generated. B7 -1 has been implicated as a necessary requirement for the generation of CD8 + CTL in the absence of help from CD4 + T cells. 31 Chen et al 9 and Townsend et al 10 demonstrated that tumor rejection by B7 -1-transfected melanoma cells was mediated primarily by CD8 + T cells, which could function in the absence of help from CD4 + cells. However, the participation of CD4 + helper T cells is required for generation of effective CTL responses. 32, 33 In the present study, we clearly demonstrated that the activation and expansion of CD4 + T cells are induced by intratumoral injection of Adex -rB7 -1. Furthermore, the number of DCs and NK cells in the regional lymph nodes of Adex -rB7 -1 -treated rats was also increased (Fig 4 ) . DCs are one of the most potent APCs. It has been suggested that DCs that had acquired antigen from apoptotic tumor cells were able to present these antigens to immune cells and induce MHC class I -restricted CTLs and anti -tumor immunity. 34, 35 Expansion of DCs in the lymph nodes of Adex -rB7 -1 -treated rats may reflect the activation of the indirect pathway of CD4 + T cell activation. In this regard, it should be pointed out that augmented expression of B7-1 on, not only tumor cells, but also host APCs is beneficial for eradicating tumor cells. NK cells also play an important role in immune response. They produce IFN -as well as exhibit cytotoxicity against certain tumor cells. 36 Yeh et al 37 and Chambers et al 38 demonstrated that the B7 -1 molecule enhanced NK cell -mediated cytotoxicity against tumor cells. Although osteosarcoma cells used in this study expressed MHC class I, which might transmit negative signaling to NK cell -mediated tumor cell killing, 39 the expansion of NK cells as well as the activation of CD4 + T cells shown in this study suggest that, not only NK cells, but also activated CD4 + T cells might elicit the production of IFN -in the regional lymph node, which favor the generation of the cellular response such as CTL.
Clinically, most patients with osteosarcoma have pulmonary micrometastasis at diagnosis. Therefore, the control of pulmonary metastasis is a major critical challenge in the treatment of osteosarcoma patients. 11 We also confirmed that the pulmonary micrometastasis was established at the time of vector injection in our model (data not shown). In the present study, it is important to note that a single intratumoral injection of Adex -rB7 -1 resulted in the induction of antimetastatic immune responses. In this regard, it should be noted that a number of lymphocytes were present around and inside not only primary tumor but also pulmonary metastatic foci of rat treated with Adex -rB7-1 ( Fig 7 ) . These observations suggest that treatment of primary tumor had a curative effect on the B7 -1-negative pre -established pulmonary metastasis of osteosarcoma. Adenovirus-mediated in vivo B7 -1 gene transfer may be of clinical value for patients with metastatic osteosarcoma.
The recombinant adenovirus is an attractive candidate for in vivo gene transfer because of the ability to transduce a wide variety of cell types.
14 Direct intratumoral injection of the vector results in efficient gene delivery and expression in the primary tumor. 40 In the present study, the efficiency of in vivo transfection with Adex -rB7 -1 was much lower than that of in vitro infection (Fig 1 ) . The improvement of efficiency and specificity of transduction into the tumor cells in vivo could significantly improve the therapeutic outcome of gene therapy in the future.
In summary, we found that adenovirus -mediated rat B7 -1 gene transfer induced ( a) expression of B7 -1 molecules in osteosarcoma cells by both in vitro and in vivo infection procedures, (b ) curative immunity against pre -established primary osteosarcoma, (c ) systemic immunity against preestablished pulmonary metastasis, and ( d) activation of regional lymph node CD4 + T cells, expansion of DCs and NK cells, and secretion of IFN -. These findings collectively support the therapeutic value of adenovirus -mediated in vivo gene transfer on osteosarcoma, which is of greater simplicity than cell -based B7 -1 vaccine, and represent an attractive strategy for therapy of patients with metastatic osteosarcama who acquired resistance to current therapeutic protocols.
